VEGFB IS A PROMISING THERAPEUTIC TARGET FOR THE TREATMENT OF DIABETES MELLITUS AND ITS COMPLICATIONS
DOI:
https://doi.org/10.21856/j-PEP.2025.1.09Keywords:
vascular endothelial growth factor B, lipotoxicity, diabetic kidney disease, diabetes mellitus, reviewAbstract
Diabetes-related complications are a significant source of morbidity and mortality worldwide. Diabetic kidney diseases a frequent complication and the main cause of renal failure in patients with diabetes. This makes the search for new effective approaches to the treatment of diabetes complications, in particular diabetic kidney disease, an important problem of modern diabetology. The aim of this study is to analyze the scientific literature data on the role of VEGFB in the pathogenesis of diabetes mellitus and its complications, in particular diabetic kidney disease, to assess the prospects of its use as a therapeutic target and to analyze the published data on the practical implementation of achievements in this area.
Materials and methods. We analyzed articles in the archives of specialized publications available on the Internet, as well as using the PubMed and Medline databases for the period from 2010 to 2024.
Results and conclusions. Numerous studies indicate a close relationship between the increase in serum and renal VEGFB levels and the development of diabetic kidney disease. It has been shown that VEGFB plays an important role in lipid and energy metabolism in normal and pathological conditions, which is associated with its involvement in the regulation of transendothelial fatty acid entry into tissues and lipid redistribution. The importance of this mechanism increases in diabetes mellitus. This leads to the excessive lipid accumulation in cells, lipotoxic effects, and damage to target tissues. It has been shown that renal lipotoxicity is an important factor in the development of diabetic kidney disease. Numerous experimental studies have shown that limiting the signaling function of VEGFB helps to reduce renal lipotoxicity and can prevent the development of diabetic kidney disease. This makes it possible to consider anti-VEGFB therapy as a new promising pharmacological approach to the treatment of diabetic kidney disease.
References
Sun H, Saeedi P, Karuranga S, et al. Diabetes Res Clin Pract 2022;183: 109119. https://doi.org/10.1016/j.diabres.2021.109119
Ong KL, Stafford LK, McLaughlin SA, et al. Lancet 2023;402: 203‐234. https://doi.org/10.1016/S0140-6736(23)01301-6
Umesh Kumar Sharma, Meenu Pujani, Anuradha J. Int J Health Sci Res 2024;14(1): 283-290. https://doi.org/10.52403/ijhsr.20240136
Cao R, Tian H, Zhang Y, et al. MedComm 2023;4(3): 283. https://doi.org/10.1002/mco2.283
Falkevall A, Mehlem A, Palombo I, et al. Cell Metab 2017;25(3): 713-726. http://dx.doi.org/10.1016/j.cmet.2017.01.004
Shen Y, Chen W, Han L, et al. Acta Pharm Sin B 2021;11(1): 127-142. https://doi.org/10.1016/j.apsb.2020.07.002
Cao Z, Zhao H, Fan J, et al. Cell Death Discov 2023;9(1): 8. https://doi.org/10.1038/s41420-023-01304-5
Lee C, Chen R, Sun G, et al. Sig Transduct Target Ther 2023;8: 305. https://doi.org/10.1038/s41392-023-01539-9
Bry M, Kivelä R, Leppänen VM, Alitalo K. Physiol Rev 2014;94(3): 779-794. https://doi.org/10.1152/physrev.00028.2013
Lal N, Puri K, Rodrigues B. Front Cardiovasc Med 2018;5: 39. https://doi.org/10.3389/fcvm.2018.00039
Robciuc MR, Kivelä R, Williams IM, et al. Cell Metab 2016;23(4): 712-724. https://doi.org/10.1016/j.cmet.2016.03.004
Wei Y, Han S, Zhou R, et al. Front Endocrinol 2022;13: 862545. https://doi.org/10.3389/fendo.2022.862545
Wu J, Wei H, Qu H, et al. J Endocrinol Invest 2017;40(11): 1219-1226. https://doi.org/10.1007/s40618-017-0677-z
Sung HK, Doh KO, Son JE, et al. Cell Metab 2013;17(1): 61-72. https://doi.org/10.1016/j.cmet.2012.12.010
Chen Y, Li X, Zhang J. J Endocrinol 2023;258(1): e220329. https://doi.org/10.1530/JOE-22-0329
Hagberg CE, Falkevall A, Wang X, et al. Nature 2010;464(7290): 917-921. https://doi.org/10.1038/nature08945
Lu X, Hu S, Liao Y, et al. Am J Physiol Endocrinol Metab 2020;319(6): E1031-E1043. https://doi.org/10.1152/ajpendo.00090.2020
Shang R, Rodrigues B. Biomolecules 2021;11(7): 1016. https://doi.org/10.3390/biom11071016
Shang R, Lee CS, Wang H, et al. Arterioscler Thromb Vasc Biol 2024;44(1): 177-191. https://doi.org/10.1161/ATVBAHA.123.319972
Moessinger C, Nilsson I, Muhl L, et al. EMBO Rep 2020;21(7): e49343. https://doi.org/10.15252/embr.201949343
Hagberg CE, Mehlem A, Falkevall A, et al. Nature 2012;490(7420): 426-430. https://doi.org/10.1038/nature11464
Jia JD, Jiang WG, Luo X, et al. World J Diabetes 2021;12(4): 480-498. https://doi.org/10.4239/wjd.v12.i4.480
Lieben L. Nat Rev Nephrol 2017;13: 194 https://doi.org/10.1038/nrneph.2017.22
Sun Y, Cui S, Hou Y, Yi F. Kidney Dis (Basel) 2021;7(6): 438-451. https://doi.org/10.1159/000518132
Chen N, Mu L, Yang Z, et al. J Cell Physiol 2021;236(1): 625-640. https://doi.org/10.1002/jcp.29890
Ge M, Fontanesi F, Merscher S, Fornoni A. Front Physiol 2020;11: 732. https://doi.org/10.3389/fphys.2020.00732
Lee HS, Suh JY , Kang BC, Lee E. Am J Physiol Renal Physiol 2021;320(4): 548-558. https://doi.org/10.1152/ajprenal.00509.2020
Palazhy S, Viswanathan V. Diabetes Metab J 2017;41(2): 128-134. https://doi.org/10.4093/dmj.2017.41.2.128
Gil CL, Hooker E, Larrivée B. Kidney Med 2020;3(1): 105-115. https://doi.org/10.1016/j.xkme.2020.10.005
Ghose S, Satariano M, Korada S, et al. Am J Physiol Endocrinol Metab 2024;326(6): E791-E806. https://doi.org/10.1152/ajpendo.00026.2024
ISSN 
ISSN 
